Notification of Admission of Shares and TVR
Solvonis Therapeutics plc has announced the admission of 1,093,333,333 new ordinary shares to the London Stock Exchange's Main Market, bringing the total number of shares in issue to 7,899,736,826 as of September 30, 2026. These new shares are fully fungible with existing ordinary shares and were admitted on August 28, 2026. The total number of voting rights in the company is now 7,899,736,826, which shareholders can use for notification calculations under FCA rules.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
LONDON - 30 September 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that further to the Company's announcement on 25 August 2026 regarding the allotment and admission of new Ordinary shares, provides the following additional information in accordance with the Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.
| 1 | Details of the issuer | |
| a) | Name | Solvonis Therapeutics plc |
| b) | LEI | 2138005PH7OJRCRPUD88 |
| 2 | Details of the transferable securities admitted to trading | |
| a) | Name, type and identification code | Ordinary Shares; ISIN: GB00BMD1Z199 |
| b) | Regulated market | London Stock Exchange - Main Market |
| c) | Number of further securities admitted | 1,093,333,333 ordinary shares |
| d) | Total number of securities in issue following admission | 7,899,736,826 |
| e) | Fungibility | Fully fungible with existing Ordinary Shares |
| 3 | Admission details | |
| a) | Date of admission | 28 th August 2026 |
| b) | Prospectus information | Prospectus: N/A Supplementary: N/A Company's website: https://solvonis.com/ |
| c) | Coverage of notification | All admissions up to and including 28 th August 2026 |
Total Voting Rights
In accordance with the Financial Conduct Authority's ("FCA") Disclosure and Transparency Rules, the Company hereby announces that as at 30 September 2026 there were 7,899,736,826 ordinary shares of £0.001 each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 7,899,736,826.
The above figure of 7,899,736,826 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The Directors of the Company are responsible for the release of this announcement.
| solvonis.com | X |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.